These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 7947045)

  • 1. Reversible renal failure in renal transplant patients receiving oral acyclovir prophylaxis.
    Ahmad T; Simmonds M; McIver AG; McGraw ME
    Pediatr Nephrol; 1994 Aug; 8(4):489-91. PubMed ID: 7947045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
    Rubin RH; Kemmerly SA; Conti D; Doran M; Murray BM; Neylan JF; Pappas C; Pitts D; Avery R; Pavlakis M; Del Busto R; DeNofrio D; Blumberg EA; Schoenfeld DA; Donohue T; Fisher SA; Fishman JA
    Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients.
    Flechner SM; Avery RK; Fisher R; Mastroianni BA; Papajcik DA; O'Malley KJ; Goormastic M; Goldfarb DA; Modlin CS; Novick AC
    Transplantation; 1998 Dec; 66(12):1682-8. PubMed ID: 9884259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytomegalovirus prophylaxis in pediatric kidney transplantation: the Dutch experience.
    Jongsma H; Bouts AH; Cornelissen EA; Beersma MF; Cransberg K
    Pediatr Transplant; 2013 Sep; 17(6):510-7. PubMed ID: 23890076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients.
    Winston DJ; Busuttil RW
    Transplantation; 2003 Jan; 75(2):229-33. PubMed ID: 12548129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of oral acyclovir or ganciclovir therapy after preemptive intravenous ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus seropositive renal and liver transplant recipients receiving antilymphocyte antibody therapy.
    Turgeon N; Fishman JA; Basgoz N; Tolkoff-Rubin NE; Doran M; Cosimi AB; Rubin RH
    Transplantation; 1998 Dec; 66(12):1780-6. PubMed ID: 9884276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group.
    Prentice HG; Gluckman E; Powles RL; Ljungman P; Milpied N; Fernandez Rañada JM; Mandelli F; Kho P; Kennedy L; Bell AR
    Lancet; 1994 Mar; 343(8900):749-53. PubMed ID: 7907729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts.
    Balfour HH; Chace BA; Stapleton JT; Simmons RL; Fryd DS
    N Engl J Med; 1989 May; 320(21):1381-7. PubMed ID: 2541335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eradication of cytomegalovirus reactivation disease using high-dose acyclovir and targeted intravenous ganciclovir in kidney and kidney/pancreas transplantation.
    Shen GK; Alfrey EJ; Knoppel CL; Dafoe DC; Scandling JD
    Transplantation; 1997 Sep; 64(6):931-3. PubMed ID: 9326425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized trial of valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation.
    Reischig T; Kacer M; Jindra P; Hes O; Lysak D; Bouda M
    Clin J Am Soc Nephrol; 2015 Feb; 10(2):294-304. PubMed ID: 25424991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of cytomegalovirus prophylaxis with acyclovir on renal transplant survival.
    Abraham KA; O'Kelly P; Spencer S; Hickey DP; Conlon PJ; Walshe JJ
    Ren Fail; 2008; 30(2):141-6. PubMed ID: 18300112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acyclovir/cytomegalovirus immune globulin combination therapy for CMV prophylaxis in high-risk renal allograft recipients.
    Carrieri G; Jordan ML; Shapiro R; Scantlebury VP; Vivas C; Kusne S; Magnone M; McCauley J; Starzl TE
    Transplant Proc; 1995 Feb; 27(1):961-3. PubMed ID: 7879246
    [No Abstract]   [Full Text] [Related]  

  • 13. High-dose oral acyclovir prophylaxis for primary cytomegalovirus infection in seronegative renal allograft recipients.
    Vasquez EM; Sanchez J; Pollak R; Vrahnos D; Fabrega AJ; Maddux MS
    Transplantation; 1993 Feb; 55(2):448-50. PubMed ID: 8381990
    [No Abstract]   [Full Text] [Related]  

  • 14. Acyclovir prophylaxis for cytomegalovirus disease in high-risk renal transplant recipients: is it effective?
    Goral S; Ynares C; Dummer S; Helderman JH
    Kidney Int Suppl; 1996 Dec; 57():S62-5. PubMed ID: 8941924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation.
    Becker BN; Becker YT; Leverson GE; Simmons WD; Sollinger HW; Pirsch JD
    Am J Kidney Dis; 2002 May; 39(5):1088-95. PubMed ID: 11979354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients.
    Winston DJ; Wirin D; Shaked A; Busuttil RW
    Lancet; 1995 Jul; 346(8967):69-74. PubMed ID: 7603215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Open clinical trial with oral acyclovir for the prophylaxis of disease by Cytomegalovirus in low risk liver transplant recipients].
    Moreno J; Montero JL; Gavilán F; Costán G; Herrero C; Cárdenas M; Sánchez-Guijo P; Torre-Cisneros J
    Enferm Infecc Microbiol Clin; 1999 Oct; 17(8):382-5. PubMed ID: 10563084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acyclovir in preventing cytomegalovirus infection in kidney transplant recipients: a case-controlled study.
    Legendre C; Ducloux D; Ferroni A; Chkoff N; Geffrier C; Rouzioux C; Kreis H
    J Med Virol; 1993; Suppl 1():118-22. PubMed ID: 8245876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytomegalovirus disease prophylaxis in renal transplantation by high dose oral acyclovir: efficacy and limits.
    Bertoni E; Rosati A; Zanazzi M; Moscarelli L; Di Maria L; Piperno R; Orsi A; Parri F; Dedola G; Salvadori M
    Transplant Proc; 1998 Aug; 30(5):2094. PubMed ID: 9723402
    [No Abstract]   [Full Text] [Related]  

  • 20. Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection.
    Reischig T; Jindra P; Mares J; Cechura M; Svecová M; Hes O; Opatrný K; Treska V
    Transplantation; 2005 Feb; 79(3):317-24. PubMed ID: 15699762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.